Idarucizumab for dabigatran reversal in patients with atrial fibrillation undergoing emergency surgery for acute aortic syndrome

Polskie Archiwum Medycyny Wewnetrznej

Volumn 126, Issue 7-8, 2016, Pages 579-581

  Mazur, Piotr ^a,b   Darocha, Tomasz ^b   Filip, Grzegorz ^b   Grudzień, Grzegorz ^a,b   Drwiła, Rafał ^a,b   Kapelak, Bogusław ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DABIGATRAN; DIURETIC AGENT; DOBUTAMINE; EPINEPHRINE; FRESH FROZEN PLASMA; IDARUCIZUMAB; MILRINONE; NORADRENALIN; THROMBOCYTE CONCENTRATE; ANTICOAGULANT AGENT; MONOCLONAL ANTIBODY;

ACUTE AORTIC SYNDROME; AGED; ANTICOAGULANT THERAPY; AORTA ANEURYSM; AORTA RECONSTRUCTION; ATRIAL FIBRILLATION; BLEEDING; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CARDIOPULMONARY BYPASS; CASE REPORT; COMORBIDITY; DEATH; DEEP HYPOTHERMIC CIRCULATORY ARREST; DRUG BLOOD LEVEL; EMERGENCY SURGERY; HEART OUTPUT; HOSPITAL DISCHARGE; HUMAN; LETTER; MALE; PEROPERATIVE COMPLICATION; PNEUMONIA; POSTOPERATIVE PERIOD; PULMONARY REHABILITATION; RESISTANT HYPERTENSION; RISK FACTOR; TIME TO TREATMENT; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VERY ELDERLY; AORTIC DISEASES; CHEMICALLY INDUCED; COMPLICATION; EMERGENCY; HEMORRHAGE; IMMUNOLOGY; PATHOLOGY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; AORTIC DISEASES; ATRIAL FIBRILLATION; DABIGATRAN; EMERGENCIES; HEMORRHAGE; HUMANS; MALE;

EID: 84989179743     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3470     Document Type: Letter

References (8)

1. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary- Revision 1. Eur Heart J. 2016. [Epub ahead of print].
2. Undas A, Pasierski T, Windyga J, et al. Practical aspects of new oral anticoagulant use in atrial fibrillation. Pol Arch Med Wewn. 2014; 124: 124-135.
3. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373: 511-520.
4. Vuylsteke A, Pagel C, Gerrard C, et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg. 2011; 39: 924-930.
5. Dyke C, Aronson S, Dietrich W et al. Universal definition of perioperative bleeding in adult cardiac surgery. J Thorac Cardiovasc Surg. 2014; 147: 1458-63 e1.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
7. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013; 34: 2094-2106.
8. Czubek U, Goralczyk T, Zalewski J, et al. Monitoring of anticoagulant effects of dabigatran in everyday practice: first experience in 32 Polish patients. Pol Arch Med Wewn. 2014; 124: 487-489.